Aakaar Medical Technologies Ltd

- Targeting 25%-30% growth momentum in FY26, aiming to retain a strong CAGR over the next 3 years. - EBITDA margins are expected to improve or at least maintain the 16% level achieved in FY25, despite short-term pressure from foreign exchange and bulk billing impacts. - Focus on stringent credit control and reducing receivable days from 130 to below 100 to improve cash flow and profitability. - New product launches, including USFDA-approved injectables and subscription-based devices, will boost revenue and margins. - Building strong brand recognition to convert doctor-driven brands to OTC, enhancing market penetration and revenue. - Operational leverage expected as increased headcount productivity improves over 1-2 years. - EBITDA and PAT expected to improve in H2 FY26 due to seasonality and inventory normalization. - Long-term ambition to reach INR 1,000 crore revenue benchmark and become the number one Indian aesthetic company.

The transcript does not explicitly mention the current or expected order book or pending orders in specific numbers. However, relevant points indicating demand and order trends include: - Demand starts increasing post-Diwali due to seasonal factors, typically in H2. - Sales team converts demand daily; no corporate-level bulk ordering mentioned. - Inventory in the market is reducing due to stringent control on receivables. - There is an anticipated upside in demand and revenue in the second half of the fiscal year. - Company aims to maintain a 25%-30% CAGR growth over the next 3 years. - Added around 900 new customers in the first half of the year; over 2,600 last year. - Working on broader customer base and strict receivable controls to improve cash flow. - New product launches with USFDA approvals expected to boost future order inflows. No specific figures on order backlog or pending orders are disclosed.

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company completed a successful IPO on NSE Emerge platform in June 2025, raising INR 27 crores. - These funds are being used strategically to strengthen working capital, improve utility, reduce short-term borrowings, and invest in new projects. - The company appears focused on improving cash flows and receivable days rather than raising additional funds at this time. - No direct references to upcoming debt or equity fundraising plans were made by management during the call.

- Aakaar Medical Technologies has invested in infrastructure including its own logistics supply chain, software for billing, reporting, and MIS. - Post-funding, the company has relaxed in terms of working capital and plans to invest significantly in marketing, especially Direct-to-Consumer (D2C) marketing to create the market. - They are focusing on building doctor-driven credibility rather than immediate e-commerce presence, aiming for organic growth without burning money on online marketing initially. - The company is investing in backend operations and technology to support collaboration with multinational companies to launch their brands in India. - They have launched new devices such as triposcopic and dermatoscopic devices with subscription models, pending full-scale launch. - The company is working on strict credit control aiming to reduce receivable days and improve cash flow, which will support future capital deployment. - No explicit large-scale capex figures or specific strategic investments are detailed, but emphasis on brand-building, distribution infrastructure, and digital marketing are clear focus areas.

- Targeting 25%-30% CAGR growth over the next 3 years, aiming to maintain growth momentum. - Confident in ending FY26 on a positive note with better revenue than FY25, despite current stringent credit controls affecting short-term sales. - Added around 900 new customers in H1 FY26 and 2,600+ customers in the prior year, indicating strong customer base expansion. - Investing in new product launches, including FDA-approved dermal fillers and botulinum toxins, expected to boost market share and revenue. - Expanding home care and consumable product categories to increase per customer usage and overall sales. - Focused on improving cash flow and reducing receivable days to below 100 to promote sustainable growth. - Building infrastructure and increasing marketing to enhance brand visibility and consumer demand. - Leveraging partnerships with multinational companies to scale sales through doctor-driven channels.